Don't look for the logo to boost reputation, says Pfizer PR

Share this article:
Don't look for the logo to boost reputation, says Pfizer PR
Don't look for the logo to boost reputation, says Pfizer PR
Authenticity and earned media trump slick corporate ads when it comes to bolstering corporate reputation, said Pfizer's Sally Susman.

Speaking at a PR summit at Pfizer HQ yesterday, Susman, SVP and chief communications officer for Pfizer, emphasized the importance of “return on reputation” and said corporate ads don't work.

“If we pay, it's immediately tainted,” said Susman, describing the reputational challenges Big Pharma must contend with in terms of public reception. “I don't want my logo on things.” She noted that Edelman's annual Trust Barometer found public trust of healthcare providers plunged this year.

As an alternative, Susman pointed to Pfizer's “Maintain” program, which offers free prescriptions to customers that were laid off prior to January 1, 2009. The program was initiated by George Puente, a doctor and regional president of worldwide pharmaceuticals at Pfizer, who conceived of the idea and served as a spokesman for its launch. “George is not a slick spokesman,” said Susman, emphasizing the importance of authentic storytelling as a communication strategy.

Addressing the sour reputation of pharma, which the public views as “greedy, arrogant and deceitful people who care only about money,” Susman countered that Pfizer “does care about profits, but we spend a lot more time talking about science, health and prevention.”

Instead of focusing solely on ROI as a metric for successful PR, Susman suggested the addition of an ROR metric: return on reputation.

Susman was speaking at a conference hosted by ExL Pharma on July 27 – 28.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.